Adverse events, such as hypoglycemia, cancer, pancreatitis, and heart failure were similar with alogliptin and placebo ( The Sitagliptin CVOT In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study, 14,671 patients with type 2 diabetes and established cardiovascular disease were randomized to addition of sitagliptin or placebo to existing therapy for a median follow-up period of 3.0 years
Doses most commonly fall between one and three grams per day
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms
Karimi, M., et al
10.1038/srep40227 32 HannaD.KumarR.BanerjeeR
However, it should not replace medically approved weight management strategies